Profiling non-small cell lung cancer: From tumor to blood

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 790-792

  Tsui, Dana W Y ^a   Berger, Michael F ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB;

ARTICLE; BLOOD CANCER CELL; CANCER RESEARCH; CELL FREE SYSTEM; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LUNG BIOPSY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR BIOPSY; GENETICS; LUNG TUMOR; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84964304531     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2514     Document Type: Article

References (12)

1. Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 2016;22:915-22.
2. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-51.
3. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole T, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumorDNAas a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
4. Mok T,WuYL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015;21: 3196-203.
5. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21.
6. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15:2630-6.
7. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84.
8. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
9. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
10. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino- Kenudson M, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015;5:713-22.
11. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112-23.
12. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251-64.